Microglia in the Rostral Ventromedial Medulla Mediate Synaptic Pruning via the C1q/C3-CR3 Signaling Pathway-A

Xilu Huang1,2,3, Jie Zeng1, Zhanwei Hu1,2,3

  • 1Department of Anesthesiology, Stomatological Hospital of Chongqing Medical University, Chongqing, China.

PubMed

Insights

Chronic orofacial pain involves microglia and C1q in the RVM, leading to synapse loss. Treatments ANX-005 and minocycline restored pain thresholds by modulating this pathway.

Area of Science:

  • Neuroscience
  • Immunology
  • Pain Research

Background:

  • Chronic orofacial pain is a debilitating condition with complex underlying mechanisms.
  • The rostral ventromedial medulla (RVM) plays a crucial role in pain modulation.
  • Microglia activation and complement system components like C1q are implicated in neuroinflammation and pain.

Purpose of the Study:

  • To investigate the role of activated microglia, C1q, and neuronal interactions in the RVM in the chronification of orofacial pain.
  • To examine the therapeutic potential of ANX-005 and minocycline in mitigating pain and associated synaptic changes.

Main Methods:

  • Rats with orofacial pain induced by complete Freund's adjuvant (CFA) were used.
  • Stereotactic injections of ANX-005 and minocycline into the RVM were administered.
  • Pain thresholds, C1q/C3 expression, microglia activation, and dendritic spine morphology were assessed.

Main Results:

  • CFA induced a significant decrease in pain threshold, accompanied by increased C1q/C3 and microglia in the RVM.
  • ANX-005 and minocycline treatment restored pain thresholds and reduced C1q/C3 and microglia levels.
  • These treatments also decreased excitatory presynaptic markers and dendritic spine density, while increasing spine density upon recovery.

Conclusions:

  • Orofacial pain chronification involves microglia-mediated pruning of excitatory synapses in the RVM via the C1q/C3-CR3 pathway.
  • This pruning disrupts the balance of descending pain modulation, favoring facilitation and leading to chronic pain.
  • ANX-005 and minocycline show promise in treating chronic orofacial pain by targeting this neuroinflammatory pathway.